% | $
Quotes you view appear here for quick access.

Celldex Therapeutics, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • biotech_invest biotech_invest Nov 19, 2010 2:15 PM Flag

    recently I bought CLDX based on my general

    technically I agree, phase II is not phase III.
    for this phase II trial
    Primary Outcome Measures:
    * Progression-free survival status [ Time Frame: 5.5mo ] [ Designated as safety issue: No ]

    Dendreon won because the median survival time for Provenge patients was 25.8 months comparing to 21.7 months for placebo-treated patients i.e. +22%
    If we see +22% survival time for Drug: PF-04948568 (CDX-110) with GM-CSF against comparator Drug: temozolomide I think it will be very good results.
    CLDX treatment is much cheaper than Provenge. CDX-110 designed for Glioblastoma Multiforme, but they can attach the antigen prostatic acid phosphatase (PAP) to their antibodies and test them on prostate cancer.

4.19+0.11(+2.70%)Apr 28 4:00 PMEDT